Across 99,648 Korean women (91.3% premenopausal) followed a median 7.75 years, 1,094 developed breast cancer. Metabolic syndrome component count (HR 1.05 per component, 95% CI 0.97-1.14), HOMA-IR (1.01 per log unit), and hs-CRP (0.98 per log unit) showed no association. ApoB and the ApoB/ApoA1 ratio were modestly inverse (HR 0.94 per SD, upper bound 1.00), but the signal vanished in a 3-year landmark analysis (0.99). The fatty-liver estimate rested on only 38 exposed cases.
The useful message is a null: the metabolic fallout of excess adiposity does not appear to carry the protective-before-menopause pattern that body mass index itself shows, nor the increased risk seen afterward. That fits a view in which adiposity's effects on breast cancer run largely through sex hormones and local estrogen biology rather than insulin resistance or systemic inflammation. The borderline ApoB signal looks like reverse causation, since cancer-related changes in lipids before diagnosis would produce exactly this attenuation under landmarking. Caveats matter: follow-up is short for a disease with long latency, most participants were premenopausal, so the postmenopausal question stays open, and single baseline measurements in a health-screening population limit inference. ApoB and LDL were near-collinear (r = 0.944), so no lipid-specific conclusion is possible. Editorially, this is confirmatory and reassuring rather than actionable. Women need not worry that metabolic syndrome or insulin resistance independently raises breast cancer risk at young ages, but those conditions still warrant treatment for cardiovascular and diabetes prevention.